Gliomas encompass those brain and spinal tumors originating in glial cells. Less aggressive low grade gliomas (LGGs) generally have better outcomes versus high grade gliomas (HGGs), such as glioblastoma (GBM). Both LGGs and HGGs are treated with resection, radiation, and chemotherapy. Beyond these options, the Optune device is also available for both newly diagnosed and recurrent GBM. Current development for gliomas is heavily focused on GBM, with clinical trials spanning multiple mechanisms of action and targets.
Oncology Resource Group (ONCrg) is a team of expert analysts who rigorously evaluate the latest corporate reports, news, and data presentations to distill out important advances in complex therapeutic areas. Our comprehensive medical congress coverage, and continuous market surveillance put these advances into the context of an overarching competitive landscape in gliomas to help guide strategic and tactical commercial development decisions for market participants.